A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

British Journal of Cancer

Volumn 87, Issue 6, 2002, Pages 608-614

  Schoemaker, N E ^a,b   Van Kesteren, C ^a,b   Rosing, H ^b   Jansen, S ^b   Swart, M ^a   Lieverst, J ^a   Fraier, D ^c   Breda, M ^c   Pellizzoni, C ^c   Spinelli, R ^c   Grazia Porro, M ^d   Beijnen, J H ^a,b,e   Schellens, J H M ^a,e   Ten Bokkel Huinink, W W ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Global Drug Metabolism   (Italy)

^d Pharmacia   (Italy)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Camptothecin; Controlled release; Drug conjugate; MAG CPT; Pharmacokinetics; Polymer

Indexed keywords

CAMPTOTHECIN; METHACRYLOYLGLYCINAMIDE; METHACRYLOYLGLYCINAMIDE CAMPTOTHECIN; POLYMER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER DISEASE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INFUSION; DRUG SOLUBILITY; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEPHROTOXICITY; PRIORITY JOURNAL; SOLID TUMOR;

ACRYLAMIDES; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; URINARY BLADDER DISEASES;

EID: 18544376660     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600516     Document Type: Article

References (21)

1. Caiolfa VR, Zamai M, Fiorino A, Frigerio E, Pellizzoni C, d'Argy R, Ghiglieri A, Castelli MG, Farao M, Pesenti E, Gigli M, Angelucci F, Suarato A (2000) Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 65: 105-119
2. Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33: 245-259
3. Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL (1998) Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethyulene glycol via a glycine linker. Cancer Chemother Pharmacol 42: 407-414
4. Conover CD, Greenwald RB, Pendri A, Sum K (1999) Camptothecin delivery systems: The utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-cancer Drug Design 14: 499-506
5. Houghton PJ, Cheshire PJ, Hallman II JD, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumours. Cancer Chemother Pharmacol 36: 393-403
6. Kehrer DF, Soepenberg O, Loos WJ, Verweij J, Sparreboom A (2001) Modulation of camptothecin analogs in the treatment of cancer: a review. Anti-Cancer Drugs 12: 89-105
7. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher MJ, Caranfa FL, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1990) Synthesis of water soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98-107
8. Lott RS, Hayton WL (1978) Estimation of creatinine clearance from serum creatinine concentration. Drug Intel Clin Pharm 12: 140-150
9. Meerum Terwogt JM, ten Bokkel HuininkWW, Schellens JHM, Schot M, Mandjes IAM, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH (2001) Phase I clinical study of PNU 166945, a novel water-soluble polymer conjugated prodrug of paclitaxel. Anticancer Drugs 12: 315-323
10. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Reports 56: 95-101
11. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Reports 56: 515-521
12. NCI (1998) Guidelines for Reporting of Adverse Drug Reactions. National Cancer Institute, Division of Cancer Treatment, Bethesda, MD, USA
13. Rivory LP, Robert J (1995) Melcular cellular clinical aspects of the pharmacology of 20 (S)Camptothecin and its derivatives. Pharmac Ther 68: 269-296
14. Schoemaker NE, Frigerio E, Fraier D, Schellens JHM, Rosing H, Jansen S, Beijnen JH (2001) High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-Camptothecin) and free camptothecin in human plasma. J Chrom B 763: 173-183
15. Seymour LW (1992) Passive tumor targetting of soluble macromolecules drug conjugates. Crit Rev Ther Drug Carrier Sys 9: 135-187
16. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accellerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147
17. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291
18. Traub SL, Johnson CE (1980) Comparison of methods of estimating creatinine clearance in children. Am J Hosp Pharm 37: 195-201
19. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J (1999) Phase I clinical and pharmacodynamic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin Cancer Res 5: 83-94
20. Wall ME, Wani MC (1996) Camptothecin Discovery to clinic. Ann NY Ac Sc 803: 1-12
21. WHO (1979) WHO handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, Switzerland